SCHEMBL5484325

SCHEMBL5484325

CC1CN(C(=O)c2ccc(-c3cnc(N)c(OC(C)c4c(Cl)ccc(F)c4Cl)c3)cc2)CCN1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 15/20 0.84
JAK2 O60674 4/20 0.62
ALK Q9UM73 6/20 0.57
INSR P06213 3/20 0.57
MAP4K3 Q8IVH8 2/20 0.57
PLK4 O00444 2/20 0.57
AURKA O14965 2/20 0.57
DCLK1 O15075 2/20 0.57
PRKD3 O94806 2/20 0.57
ABL1 P00519 2/20 0.57
NTRK1 P04629 2/20 0.57
LCK P06239 2/20 0.57
FES P07332 2/20 0.57
CSF1R P07333 2/20 0.57
LYN P07948 2/20 0.57
RET P07949 2/20 0.57
IGF1R P08069 2/20 0.57
ROS1 P08922 2/20 0.57
SRC P12931 2/20 0.57
FER P16591 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30453276 0.92 MET (1.00) METJAK2ALKINSRMAP4K3
SCHEMBL30454334 0.92 MET (1.00) METJAK2ALKINSRMAP4K3
SCHEMBL488336 0.92 MET (1.00) METJAK2ALKINSRMAP4K3
SCHEMBL488041 0.92 MET (1.00) METJAK2ALKINSRMAP4K3
SCHEMBL5252099 0.91 MET (0.80) METJAK2ALKINSRMAP4K3
SCHEMBL30452860 0.91 MET (0.80) METJAK2ALKINSRMAP4K3
SCHEMBL3113354 0.91 MET (0.80) METJAK2ALKINSRMAP4K3
SCHEMBL488694 0.91 MET (0.80) METJAK2ALKINSRMAP4K3
SCHEMBL30453504 0.89 MET (0.75) METJAK2ALKINSRMAP4K3
SCHEMBL488666 0.89 MET (0.75) METJAK2ALKINSRMAP4K3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7230098-B2 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. (US) 2007-06-12 US disclosed
US-20050009840-A1 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009840-A1 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer MET, ERBB2, CDK4 MET 1/4885JAK2 8/4885ALK 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.